Neuropsychiatric Adverse Effects of Mefloquine: What Do We Know and What Should We Do?

ISSN： 1172-7047

Source： CNS Drugs, Vol.11, Iss.1, 1999-01, pp. : 1-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dilemmas about the toxicological consequences of metal-on-metal hip prostheses - What we do and do not know, and what we should do?

By Brent Jeffrey

Clinical Toxicology, Vol. 51, Iss. 4, 2013-05 ,pp. : 195-198

Informa Healthcare

Access to resources Recommend Favorite

Prevention and Pharmacovigilance: What Should We Do, What Can We Do?

By Edwards I. Ralph

Drug Safety, Vol. 35, Iss. 2, 2012-02 ,pp. : 87-90

Adis International

Access to resources Recommend Favorite

The diabetic heart - what is to blame and what can we do?

Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Penetration of Antibacterials into Bone: What Do We Really Need to Know for Optimal Prophylaxis and Treatment of Bone and Joint Infections?

By Pea Federico

Clinical Pharmacokinetics, Vol. 48, Iss. 2, 2009-01 ,pp. : 125-127

Adis International

Access to resources Recommend Favorite

Drug-Resistant Tuberculosis: What Do We Do Now?

By Telenti A.

Drugs, Vol. 59, Iss. 2, 2000-02 ,pp. : 171-179

Adis International

Access to resources Recommend Favorite